Adenosine deaminase (ADA) perpetuates chronic inflammation by degrading extracellular adenosine which is toxic for lymphocytes. ADA has two distinct conformations: open form and closed form [1]. From the crystal structures with various ligands, the non-nucleoside type inhibitors bind to the active site occupying the critical water-binding position and sustain the open form of apo-ADA. In contrast, substrate mimics do not occupy the critical position, and induce the large conformational change to the closed form. However, it is difficult to predict the binding of (+)-erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA), as it possesses characteristic parts of both the substrate and the non-nucleoside inhibitors. The crystal structure shows that EHNA binds to the open form through a novel recognition of the adenine base accompanying conformational change from the closed form of the PR-ADA complex in crystalline state [2]. The open form crystal structure of the EHNA-ADA complex supports our hypothesis that the occupancy at the trigger-water-position is critical for determining the open/closed conformational alternation, rather than the nucleoside framework binding. We believe that the structural penetration of the EHNA-ADA complex and structural comparison of the other inhibitor-ADA complexes will support the discovery of novel ADA inhibitors by structure-based drug design.
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[1] T. Kinoshita, et al, Biochemistry 44, 2005, 10562- , an ATP analogue (AMPPCP), and cyclopiazonic acid (CPA) . The structure determined at 2.5 Å resolution leads to a significantly revised model of CPA binding compared to earlier reports [1, 2] showing that a divalent metal ion is required for CPA binding through coordination of the tetramic acid moiety at a characteristic kink of the M1 helix found in all P-type ATPase structures which is expected to be part of the cytoplasmic cation access pathway. Our model is consistent with the biochemical data on CPA [3] Protein kinase CK2alpha is a highly pleiotropic serine/ threonine protein kinase. CK2alpha plays important roles in cell growth, proliferation, and survival, while it is highly expressed in a wide variety of tumors.(1) Furthermore, CK2alpha is a target protein for glomerulo nephritis (GN) therapy, because an administration of either anitisense oligodeoxynucleotide against CK2alpha or low molecular weight CK2alpha-specific inhibitors effectively prevents the progression of renal pathology in the rat GN models. (2) To design a novel and potent CK2alpha inhibitor, we determined four X-ray crystal structures of CK2alpha-inhibitor complexes (cc-04791, cc-04820, apigenin, ellagic acid), and measured enzyme kinetic parameters using ITC (Isothermal Titration Calorimetry) for the respective , there has been a move to determine the role these molecules play in telomere regulation. We report here the first crystal structure of a telomeric RNA G-quadruplex, providing atomic-resolution insights into RNA-quadruplex folding. The structure, formed from the sequence r(U Br AGGGUUAGGGU), folds as a bimolecular, parallel stranded G-quadruplex with linking propeller-type external loops, a topology previously observed for the equivalent telomeric DNA sequence [3] . As telomeric DNA G-quadruplexes are well established targets for small molecule anti-cancer therapeutics, it is reasonable to consider telomeric RNA G-quadruplexes as potential targets too. The structure reported here provides the basis for computer aided drug design, and will hopefully allow the differences between RNA and DNA G-quadruplexes to be identified and exploited for improved specificity of quadruplex-interacting ligands. These issues will be addressed and the structural basis for drug design explored.
[1] Azzalin, C.M., Reichenbach, P., Khoriauli, L., Giulotto, E., Lingner, J., Science, 2007, 318, 798. [2] Schoeftner, S., Blasco, M.A., Nat Cell Bio, 2008 , 10, 228. [3] Parkinson, G.N., Lee, M.P.H., Neidle, S., Nature, 2002 Keywords: RNA structure; anticancer drug structural study; drug targets inhibitors. Thermodynamic data, specifically enthalpy (ΔH) and entropy (ΔS), reveal the forces that drive complex formation. Furthermore, binding affinity -K d in range of millimolar to nanomolar is a powerful information for drug design targeting highly homologous kinases. Supported with computational analysis, these data show the specific contributions of some important residues in ligand-binding, and lead to design a potent inhibitor.
[1] Duncan, J. S. The glutathione transferases (GSTs) are detoxification enzymes that protect the cell from a wide range of potentially harmful electrophilic compounds [1] . Although this action of GSTs protects the organism from harmful environmental toxins, it results also in neutralization of certain therapeutic drugs such as chlorambucil, an anti-cancer drug used to treat chronic lymphocytic leukemia (CLL) [2] . Design of GST inhibitors that mimic chlorambucil binding may be useful in improving the bioavailability of chlorambucil when they are co-administered with the drug. To enable structure-based design of such inhibitors, human GST A1-1 was crystallized in the presence of glutathione and chlorambucil and its structure was determined at 2.3 Å resolution. Chlorambucil is observed to form a conjugate with glutathione, adopting a conformation different from the one observed in the structure of GST P1-1 and to induce local conformational changes in nearby protein residues. In addition it reacts with the only cysteine residue of the enzyme, in agreement with biochemical evidence.
